Lunit, an AI-driven medical device maker, said on Monday it has recruited international healthcare experts to reinforce its global business.

The company hired many talented people from biotech firms, regulatory agencies, and medical institutions to strengthen global competitiveness, it said.

Lunit recently appointed Ken Nesmith as a chief business officer (CBO) of Lunit SCOPE, Marcus Skovhus as vice president of corporate development, and Park Su-bok as director of clinical strategy at Lunit INSIGHT.

Nesmith will oversee the business of Lunit SCOPE, an AI biomarker platform. He was co-founder and CEO of Lexent Bio, a liquid biopsy company acquired by Foundation Medicine (FMI), a subsidiary of Roche.

As vice president, Skovhus will establish a long-term business strategy to accelerate Lunit’s growth. He is a biotech expert with over 10 years of experience in the healthcare sector. He was in charge of corporate strategy and portfolio planning at FMI and planned and executed various M&A deals.

Park, director of clinical strategy, received Ph.D. in applied mathematics. She worked at the FDA as an expert in AI and medical imaging device regulation for 16 years. Based on her experience in radiographic imaging research and AI-powered software evaluation and regulatory strategy, she is expected to assess Lunit INSIGHT’s AI imaging analysis solutions and establish regulation strategies.

Lunit also recruited Mark Germain, managing director of Aentib Group, and Chae Young-kwang, a professor at Northwestern University Feinberg School of Medicine, as new members of its advisory board.

According to Lunit, Germain co-founded and listed more than 10 biotech companies on Nasdaq, and their combined market capitalization is valued at over 50 trillion won ($42.19 billion). In addition, he serves as chairman and a board member of biotech companies, including BiondVax Pharmaceuticals and Pluristem Therapeutics. He also serves as chairman of the board of directors and an investor of over 20 biotech companies.

Chae is an oncology professor at Northwestern University Feinberg School of Medicine and co-director of Lurie Cancer Center of Northwestern University. He published more than 100 medical papers on medicines and biomarkers and participated in more than 115 studies on personalized precision medicine and combination therapy. At the American Society of Clinical Oncology (ASCO) Annual Meeting 2020, he presented the abstracts of the study on Lunit SCOPE’s immunotherapy predictor.

“With many experts in global healthcare, medicine, and regulation joining us, we expect that Lunit’s AI products will enter the global market faster,” said Suh Beom-seok, CEO of Lunit. “We will continue to recruit talented people in various fields to expand our business in the global market quickly.”